Rigel Pharmaceuticals's quarterly market cap
declined
from Jun. 2023 ($224.9 Mil) to Sep. 2023 ($188.3 Mil) but then
increased
from Sep. 2023 ($188.3 Mil) to Dec. 2023 ($253.5 Mil).
Rigel Pharmaceuticals's annual market cap
declined
from Dec. 2021 ($454.7 Mil) to Dec. 2022 ($260.1 Mil) and
declined
from Dec. 2022 ($260.1 Mil) to Dec. 2023 ($253.5 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Rigel Pharmaceuticals's Enterprise Value for Today is $196.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Rigel Pharmaceuticals's Market Cap
For the Biotechnology subindustry, Rigel Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rigel Pharmaceuticals's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Rigel Pharmaceuticals's Market Cap falls into.
Rigel Pharmaceuticals Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Rigel Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rigel Pharmaceuticals (NAS:RIGL) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Rigel Pharmaceuticals Market Cap Related Terms
Thank you for viewing the detailed overview of Rigel Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Rigel Pharmaceuticals (Rigel Pharmaceuticals) Business Description
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RIGL has been successfully added to your 